Long-term results of maintenance treatment of mitomycin C or alternating mitomycin C and bacillus Calmette–Guérin instillation therapy of patients with carcinoma in situ of the bladder: A subgroup analysis of the prospective FinnBladder 2 study with a 17-year follow-up
- 2 July 2012
- journal article
- research article
- Published by Taylor & Francis Ltd in Scandinavian Journal of Urology and Nephrology
- Vol. 46 (6), 411-417
- https://doi.org/10.3109/00365599.2012.694906
Abstract
Only a few studies with a long-term follow-up exist on patients with carcinoma in situ (CIS) treated with instillation therapy. The objective was to study the long-term outcome of patients with CIS after mitomycin C (MMC) monotherapy or alternating therapy with MMC and bacillus Calmette-Guérin (BCG). The study population comprised 68 patients with CIS belonging to a larger material of 256 patients with non-muscle-invasive bladder carcinoma who were randomized between 1987 and 1992 in a prospective multicentre study. Patients received the same induction period with MMC and continued with maintenance treatment comprising either monthly instillations of MMC alone or alternating MMC and BCG instillations for up to 2 years. Primary endpoints were cancer-specific and overall mortality. Secondary endpoints were time to first recurrence and time to progression. The principal statistical methods were the Kaplan-Meier method and cumulative incidence analysis. The overall median follow-up time of the patients with CIS was 7.2 years and the median follow-up time of the patients still alive was 17.1 years. The non-stratified probability of dying from bladder carcinoma at 5, 10 and 15 years was 13%, 25% and 28%, respectively. No significant difference was found between the study groups with respect to time to first recurrence, progression, or disease-specific or overall mortality. The long-term bladder cancer-specific mortality was unexpectedly low despite the relatively ineffective instillation therapy and the poor outcome of the patients after progression.Keywords
This publication has 25 references indexed in Scilit:
- The Role of Bacillus Calmette-Guérin in the Treatment of Non–Muscle-Invasive Bladder CancerEuropean Urology, 2010
- An Individual Patient Data Meta-Analysis of the Long-Term Outcome of Randomised Studies Comparing Intravesical Mitomycin C versus Bacillus Calmette-Guérin for Non–Muscle-Invasive Bladder CancerEuropean Urology, 2009
- EAU Guidelines on the Diagnosis and Treatment of Urothelial Carcinoma in SituEuropean Urology, 2005
- Intravesical bacille calmette-guérin versus mitomycin c in superficial bladder cancer: formal meta-analysis of comparative studies on tumor progressionUrology, 2004
- Intravesical Bacillus Calmette-Guerin Reduces the Risk of Progression in Patients with Superficial Bladder Cancer: A Meta-analysis of the Published Results of Randomized Clinical TrialsJournal of Urology, 2002
- Updated concepts and treatment of carcinoma in situUrologic Oncology, 1998
- Alternating Mitomycin C and Bacillus Calmette-Guerin Instillation Therapy for Carcinoma in Situ of the BladderJournal of Urology, 1995
- UROTHELIAL DYSPLASIA CONCOMITANT WITH BLADDER TUMOURS AS A DETERMINANT FACTOR FOR FUTURE NEW OCCURRENCESThe Lancet, 1983
- Optimising mitomycin C activity during intravesical instillationUrological Research, 1983
- Intravesical Instillation of Adriamycin®European Urology, 1980